

VoxCell BioInnovation Responds to FDA Shift with Human-Relevant Vascularized Models *Showcasing Next-Generation In Vitro Systems at Web Summit Vancouver*

FOR IMMEDIATE RELEASE

Victoria, BC – May 16, 2025 – VoxCell BioInnovation, a British Columbia innovator in best-in-class 3D bioprinted tissue models, will unveil its early access *in vitro* vascularized models at Web Summit Vancouver on May 28th and 29th. This product launch comes at a pivotal moment as the U.S. Food and Drug Administration (FDA) announces a bold shift in drug testing regulations, phasing out the requirement for animal testing for monoclonal antibodies and other drugs. The FDA is now championing human-relevant lab models, including 3D bioprinted vascularized models, ushering in a new standard for preclinical drug testing, increasing translation of results between the preclinical and clinical trial phases of drug development.

Traditional *in vitro* systems often fail due to their simplicity and the absence of a 3D environment and functional vasculature, limiting the ability to replicate human-relevant behaviour accurately. VoxCell's models incorporate functional, perfusable vasculature that enables the natural flow of nutrients and therapies, creating a more realistic and reliable environment that better reflects human biology and improves the accuracy of preclinical testing.

These models may do more beyond drug development, in the future the company aims to further personalized/precision medicine where tissue models could be created using a patient's own cells, to test therapies that could be best for them.

Learn more about VoxCell and its next-generation *in vitro* vascularized models at www.voxcellbio.com. To read more about the FDA's plan to phase out laboratory animal testing, view the official announcement [here](#).

Join us at Web Summit Vancouver! VoxCell will exhibit as a GROWTH company at booth G103 all day on May 28 and be featured at the BC Pavilion on May 29 from 9am - 12pm. Don't miss Founder & CEO, Dr. Karolina Valente, speaking on Thursday, May 29 at 4:15pm on the Growth Stage (Stage 6). Meet our team and discover how we're redefining drug discovery with vascularized human-based models.

About VoxCell BioInnovation

VoxCell BioInnovation is a Victoria based biotechnology company advancing *in vitro* modeling with 3D bioprinted, vascularized human-like models. Combining a proprietary bioprinter, vascularization software, and Universal Bioinks™, VoxCell creates biomimetic models that replicate patient tissue complexity. These ready-to-use models support cancer research, drug screening, and target validation, providing physiologically relevant, reproducible platforms that accelerate innovation and reduce reliance on animal testing.

About Web Summit Vancouver

Web Summit Vancouver, launching in May 2025, is the first Web Summit event in Vancouver, succeeding Collision in Toronto as North America's fastest-growing technology event. Building on the success of new events in Rio and Qatar, and the flagship event in Lisbon attracting over 70,000 attendees, Web Summit is expanding its reach. Vancouver, home to more than 11,000 tech companies and leading North America in high-tech job growth, is the ideal location to showcase innovation and foster tech industry growth.

Media Contact:

Karolina Valente
VoxCell BioInnovation
kvalente@voxcellbio.com
778-587-9955